Investors

Discover Virbac's Statement on extra-financial performance

SALES 2022
1,216 M€
60%
Companion
animals
40%
Farm
animals

(in € million)

Financial public release
& News

2023 fourth quarter consolidated sales

2024/01/17 - Financial public releases

Annual revenue growth of +4.9% thanks to record fourth-quarter activity at +11.5%

Read more

Outlook 2023-2024

2023/12/19 - Financial public releases

Read more

Virbac acquired a majority stake in Globion, a leading Indian poultry vaccines specialist

2023/11/02 - Financial public releases

Acquistion_Virbac_octobre_300x200.jpgOn November 1, we successfully finalized the acquisition of a majority stake in Globion. This transaction will bolster our position of animal health leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines. 

Read more

Events
Tuesday March 19

2023 results

From 2024/03/19

Read moreRead less

Thursday March 19, 2024 after market close

2023 results
(quiet period from February 20, 2024)​

Wednesday March 20

SFAF meeting - 2023 financial & strategic information

From 2024/03/20

Read moreRead less

Wednesday March 20, 2024
SFAF meeting - 2023 financial & strategic information
Tuesday April 16

2024 first quarter sales

From 2024/04/16

Read moreRead less

Tuesday April 16, 2024 after market close

2024 first quarter sales
(quiet period from April 2, 2024)

Past Events
Wednesday January 17

2023 fourth quarter year sales

From 2024/01/17

Read moreRead less

Wednesday January 17, 2024 after market close

2023 fourth quarter year sales
(quiet period from January 2, 2024)

For more financial information

For more financial information

finances@virbac.com